Cardioprotective agent

Abstract

A problem of the present invention is to provide an agent which allows effective protection of cardiac damage in a case where a variety of symptoms such as arrhythmia, cardiac desmoplasia and heart-failure are likely to accompany with hypertension, hypercardia, myocardial infarction, arteriosclerosis, diabetic and non-diabetic renal diseases, and re-stenosis posterior to PTCA. The agent contains an effective amount of at least one protease inhibitor to administer intravenously or orally. The protease inhibitor is preferably a serine protease inhibitor. The serine protease inhibitor is preferably a chymotrypsin-like serine protease inhibitor. Concretely, it is a chymase inhibitor such as a peptide derivative of aryl diester of alpha-aminoalkylphosphonic acid which is Suc-Val-Pro-PheP(OPh)2, and preferably the enantiormer Suc-Val-Pro-L-PheP(OPh)2.

Dependencies are inferred from the claim text.